Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Evaluating the Acceptability of a Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Study
University of Alberta
30 participants
Jan 26, 2026
INTERVENTIONAL
Conditions
Summary
CYCLE-CIPN is a proof-of-concept study designed to evaluate whether a prescribed aerobic exercise intervention has the potential to reduce the symptoms and functional impact of CIPN. The small number of participants in the proposed study will allow us to make decisions on the feasibility ("go/no-go") of a future larger-scale trial. The protocol will assess feasibility and acceptability through recruitment, completion, adherence, program satisfaction, and safety. The study will also evaluate CIPN symptoms using both patient-reported and objective outcome measures, as well as fitness and quality of life outcomes. We aim to recruit 30 participants. The Health Research Board of Alberta Cancer Committee has approved this study. Participants will participate in a stationary cycling-based aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supervised and progressive, between 30 and 60 minutes each.
Eligibility
Inclusion Criteria5
- years or older
- Cancer diagnosis stage I to III
- CIPN: grade 1 (mild)
- Receiving or have received chemotherapy treatment for cancer
- Speak, read and understand English
Exclusion Criteria6
- Medical conditions that cause additional neuropathy symptoms (i.e. diabetes)
- Any uncontrolled medical conditions
- Will undergo surgery or radiation therapy during the study period
- Are already receiving an aerobic exercise training program
- Are already participating in an exercise-based research study
- Are unable to provide signed informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A supervised 12-week cycling-based aerobic exercise intervention performed twice per week.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07150117